Omeros Corporation

OMER Real Time Price USD

N/A

...

Trade OMER

...

Overview

Financials

Insiders

Institutions

Government

Ownership

Income

Balance Sheet

Cash Flow

OMER Income Statement

OMER Balance Sheet

OMER Cash Flow

Congress Trading

Recent trades of OMER by members of U.S. Congress

No Congress Trading data for this ticker

Congress Trading Dashboard

OMER Stock Insider Trading Activity

Name	Type	Shares	Price	Shares Held	Date	Reported

OMER Stock Institutional Owners

Investor	Shares	Change in Shares	Market Value	Date	Reported

OMER Derivatives Institutional Owners

Investor	Type	Shares	Change in Shares	Market Value	Date	Reported

Whale Activity

Recently reported changes by institutional investors

Insider Trading

Quarterly net insider trading by OMER's directors and management

Corporate Lobbying

Government lobbying spending instances

$45,000 Oct 24, 2024 Issue: Medicare/Medicaid
$60,000 Oct 21, 2024 Issue: Health Issues
$80,000 Oct 21, 2024 Issue: Budget/Appropriations Medicare/Medicaid
$45,000 Oct 18, 2024 Issue: Medicare/Medicaid
$75,000 Oct 14, 2024 Issue: Health Issues Medical/Disease Research/Clinical Labs
$80,000 Oct 10, 2024 Issue: Medicare/Medicaid
$45,000 Aug 12, 2024 Issue: Medicare/Medicaid
$80,000 Jul 22, 2024 Issue: Budget/Appropriations Medicare/Medicaid
$60,000 Jul 22, 2024 Issue: Health Issues
$75,000 Jul 19, 2024 Issue: Health Issues Medical/Disease Research/Clinical Labs
$80,000 Jul 18, 2024 Issue: Medicare/Medicaid
$45,000 Jul 15, 2024 Issue: Medicare/Medicaid
$60,000 Apr 22, 2024 Issue: Health Issues
$80,000 Apr 22, 2024 Issue: Medicare/Medicaid
$45,000 Apr 21, 2024 Issue: Medicare/Medicaid
$45,000 Apr 20, 2024 Issue: Medicare/Medicaid
$80,000 Apr 17, 2024 Issue: Medicare/Medicaid
$75,000 Apr 14, 2024 Issue: Medical/Disease Research/Clinical Labs
$60,000 Jan 22, 2024 Issue: Health Issues
$45,000 Jan 22, 2024 Issue: Medicare/Medicaid
$80,000 Jan 22, 2024 Issue: Health Issues Medicare/Medicaid
$45,000 Jan 22, 2024 Issue: Medicare/Medicaid
$80,000 Jan 20, 2024 Issue: Medicare/Medicaid
$75,000 Jan 11, 2024 Issue: Medical/Disease Research/Clinical Labs
$60,000 Oct 20, 2023 Issue: Health Issues
$80,000 Oct 20, 2023 Issue: Medicare/Medicaid
$45,000 Oct 20, 2023 Issue: Medicare/Medicaid
$45,000 Oct 19, 2023 Issue: Medicare/Medicaid
$80,000 Oct 18, 2023 Issue: Medicare/Medicaid
$75,000 Oct 02, 2023 Issue: Medical/Disease Research/Clinical Labs
$45,000 Jul 20, 2023 Issue: Medicare/Medicaid
$60,000 Jul 20, 2023 Issue: Health Issues
$80,000 Jul 20, 2023 Issue: Medicare/Medicaid
$45,000 Jul 19, 2023 Issue: Medicare/Medicaid
$80,000 Jul 13, 2023 Issue: None
$45,000 Feb 23, 2023 Issue: Medicare/Medicaid
$60,000 Feb 19, 2023 Issue: Health Issues
$45,000 Jan 20, 2023 Issue: Medicare/Medicaid
$80,000 Jan 20, 2023 Issue: Health Issues Medicare/Medicaid
$80,000 Jan 20, 2023 Issue: Medicare/Medicaid
$80,000 Jan 13, 2023 Issue: Health Issues Medicare/Medicaid Medical/Disease Research/Clinical Labs
$45,000 Nov 02, 2022 Issue: Medicare/Medicaid
$60,000 Oct 20, 2022 Issue: Health Issues
$80,000 Oct 20, 2022 Issue: Health Issues Medicare/Medicaid
$45,000 Oct 19, 2022 Issue: Medicare/Medicaid
$80,000 Oct 18, 2022 Issue: Medicare/Medicaid
$80,000 Oct 08, 2022 Issue: Health Issues Medicare/Medicaid Medical/Disease Research/Clinical Labs
$60,000 Jul 20, 2022 Issue: Health Issues
$45,000 Jul 20, 2022 Issue: Medicare/Medicaid
$80,000 Jul 20, 2022 Issue: Health Issues Medicare/Medicaid
$45,000 Jul 20, 2022 Issue: Medicare/Medicaid
$80,000 Jul 18, 2022 Issue: Health Issues Medicare/Medicaid Medical/Disease Research/Clinical Labs
$80,000 Jul 18, 2022 Issue: Government Issues Medicare/Medicaid
$60,000 Apr 20, 2022 Issue: Health Issues
$80,000 Apr 20, 2022 Issue: Health Issues Medicare/Medicaid
$45,000 Apr 20, 2022 Issue: Medicare/Medicaid
$45,000 Apr 20, 2022 Issue: Medicare/Medicaid
$80,000 Apr 12, 2022 Issue: Government Issues Medicare/Medicaid
$80,000 Apr 10, 2022 Issue: Health Issues Medicare/Medicaid Medical/Disease Research/Clinical Labs
$45,000 Feb 09, 2022 Issue: Medicare/Medicaid
$60,000 Jan 20, 2022 Issue: Health Issues
$45,000 Jan 20, 2022 Issue: Medicare/Medicaid
$80,000 Jan 19, 2022 Issue: Medicare/Medicaid Health Issues
$80,000 Jan 17, 2022 Issue: Government Issues Medicare/Medicaid
$80,000 Jan 16, 2022 Issue: Medical/Disease Research/Clinical Labs Medicare/Medicaid Health Issues
$60,000 Oct 20, 2021 Issue: Health Issues
$45,000 Oct 20, 2021 Issue: Medicare/Medicaid
$80,000 Oct 20, 2021 Issue: Medicare/Medicaid Health Issues
$70,000 Oct 20, 2021 Issue: Medical/Disease Research/Clinical Labs Health Issues Medicare/Medicaid
$80,000 Oct 20, 2021 Issue: Government Issues Medicare/Medicaid
$45,000 Oct 19, 2021 Issue: Medicare/Medicaid
$45,000 Jul 21, 2021 Issue: Medicare/Medicaid
$80,000 Jul 20, 2021 Issue: Medicare/Medicaid Health Issues
$60,000 Jul 20, 2021 Issue: Health Issues
$22,500 Jul 20, 2021 Issue: Medicare/Medicaid
$80,000 Jul 18, 2021 Issue: Medicare/Medicaid Government Issues
$70,000 Jul 17, 2021 Issue: Medicare/Medicaid Health Issues Medical/Disease Research/Clinical Labs
$45,000 Apr 20, 2021 Issue: Medicare/Medicaid
$60,000 Apr 20, 2021 Issue: Health Issues
$80,000 Apr 20, 2021 Issue: Health Issues Medicare/Medicaid
$60,000 Apr 19, 2021 Issue: Health Issues Medical/Disease Research/Clinical Labs Medicare/Medicaid
$22,500 Apr 16, 2021 Issue: Medicare/Medicaid
$80,000 Apr 16, 2021 Issue: Medicare/Medicaid
$60,000 Jan 21, 2021 Issue: Health Issues
$22,500 Jan 21, 2021 Issue: Medicare/Medicaid
$80,000 Jan 21, 2021 Issue: Medicare/Medicaid Health Issues
$80,000 Jan 20, 2021 Issue: Medicare/Medicaid
$45,000 Jan 20, 2021 Issue: Medicare/Medicaid
$50,000 Jan 16, 2021 Issue: Medical/Disease Research/Clinical Labs Health Issues Medicare/Medicaid
$50,000 Dec 08, 2020 Issue: Medical/Disease Research/Clinical Labs Health Issues Medicare/Medicaid
$60,000 Oct 20, 2020 Issue: Health Issues
$80,000 Oct 20, 2020 Issue: Health Issues Medicare/Medicaid
$22,500 Oct 20, 2020 Issue: Medicare/Medicaid
$45,000 Oct 19, 2020 Issue: Medicare/Medicaid
$80,000 Oct 18, 2020 Issue: Health Issues Medicare/Medicaid
$40,000 Oct 15, 2020 Issue: Health Issues
$80,000 Jul 20, 2020 Issue: Medicare/Medicaid Health Issues
$60,000 Jul 20, 2020 Issue: Health Issues
$45,000 Jul 20, 2020 Issue: Medicare/Medicaid
$50,000 Jul 17, 2020 Issue: Health Issues

Corporate Lobbying

Estimated quarterly lobbying spending

U.S. Patents

New patents grants

Patent Title: Monoclonal antibodies, compositions and methods for detecting complement factor d Oct. 29, 2024
Patent Title: Masp-2 inhibitors and methods of use Oct. 08, 2024
Patent Title: Therapeutic antibodies that bind to the serine protease domain of masp-2 and uses thereof Sep. 17, 2024
Patent Title: Masp-2 inhibitors and methods of use Jul. 09, 2024
Patent Title: Methods for treating conditions associated with masp-2 dependent complement activation May. 14, 2024
Patent Title: Methods for inhibiting angiogenesis in a subject in need thereof May. 14, 2024
Patent Title: Chimeric inhibitor molecules of complement activation Apr. 02, 2024
Patent Title: Methods for treating and/or preventing graft-versus-host disease and/or diffuse alveolar hemorrhage and/or veno-occlusive disease associated with hematopoietic stem cell transplant Feb. 13, 2024
Patent Title: Methods for treating conditions associated with masp-2 dependent complement activation Jan. 30, 2024
Patent Title: Antibodies specifically binding to masp-3 for the treatment of various diseases and disorders Jan. 30, 2024
Patent Title: Masp-2 inhibitors and methods of use Nov. 07, 2023
Patent Title: Masp-2 inhibitors and methods of use May. 30, 2023
Patent Title: Highly concentrated low viscosity masp-2 inhibitory antibody formulations, kits, and methods Apr. 18, 2023
Patent Title: Compositions for inhibiting masp-2 dependent complement activation Mar. 28, 2023
Patent Title: Masp-2 inhibitors and methods of use Feb. 21, 2023
Patent Title: Methods of inhibiting masp-2-dependent complement activation in a subject suffering from catastrophic antiphospholipid syndrome Dec. 13, 2022
Patent Title: Treatment of addiction and impulse-control disorders using pde7 inhibitors Oct. 11, 2022
Patent Title: Chimeric inhibitor molecules of complement activation Sep. 27, 2022
Patent Title: Compositions and methods for prophylaxis and treatment of addictions Feb. 08, 2022
Patent Title: Anti-inflammatory and mydriatic intracameral solutions for inhibition of postoperative ocular inflammatory conditions Feb. 01, 2022
Patent Title: Treatment of addiction and impulse-control disorders using pde7 inhibitors Dec. 28, 2021
Patent Title: Masp isoforms as inhibitors of complement activation Dec. 21, 2021
Patent Title: Methods of generating bioactive peptide-bearing antibodies and compositions comprising the same Jun. 29, 2021
Patent Title: Antibodies specifically binding to masp-3 for the treatment of various diseases and disorders Jun. 08, 2021
Patent Title: Methods for treating and/or preventing graft-versus-host disease and/or diffuse alveolar hemorrhage and/or veno-occlusive disease associated with hematopoietic stem cell transplant May. 25, 2021
Patent Title: Chimeric inhibitor molecules of complement activation Aug. 25, 2020
Patent Title: Nucleic acids encoding antibodies specifically binding to masp-3 Aug. 18, 2020
Patent Title: Methods for inhibiting fibrosis in a subject in need thereof Aug. 11, 2020
Patent Title: Compositions for inhibiting masp-2 dependent complement activation Jun. 16, 2020
Patent Title: Antibodies specifically binding to masp-3 for the treatment of various diseases and disorders May. 05, 2020
Patent Title: Chimeric inhibitor molecules of complement activation May. 21, 2019
Patent Title: G protein coupled receptor 85 and sreb3 knockout mice and uses thereof May. 21, 2019
Patent Title: Methods for treating conditions associated with masp-2 dependent complement activation Feb. 12, 2019
Patent Title: Pde10 inhibitors and related compositions and methods Oct. 23, 2018
Patent Title: Compositions and methods for prophylaxis and treatment of addictions Sep. 04, 2018
Patent Title: Compositions for inhibiting masp-2 dependent complement activation Aug. 14, 2018
Patent Title: Solid state forms of a pde10 inhibitor Mar. 20, 2018
Patent Title: Pde10 inhibitors and related compositions and methods Jan. 30, 2018
Patent Title: Cyclooxygenase inhibitor and calcium channel antagonist compositions and methods for use in urological procedures Jan. 02, 2018
Patent Title: Stable preservative-free mydriatic and anti-inflammatory solutions for injection Jan. 02, 2018
Patent Title: Optically active pde10 inhibitor Dec. 26, 2017
Patent Title: Chimeric inhibitor molecules of complement activation Nov. 14, 2017
Patent Title: Pde10 inhibitors and related compositions and methods Oct. 10, 2017
Patent Title: Anti-fzd10 monoclonal antibodies and methods for their use Oct. 03, 2017
Patent Title: Composition and method for diversification of target sequences Jun. 13, 2017
Patent Title: Mixed micelles May. 23, 2017
Patent Title: Processes and intermediates for the preparation of a pde10 inhibitor May. 16, 2017
Patent Title: Methods for treating conditions associated with masp-2 dependent complement activation May. 09, 2017
Patent Title: Ophthalmologic irrigation solutions and method Mar. 07, 2017
Patent Title: Optically active pde10 inhibitor Nov. 15, 2016

Government Contracts

Federal grants, loans, and purchases

$0 2021-03-31 00:00:00 Agency: DEPARTMENT OF VETERANS AFFAIRS (VA)

Government Contracts

Estimated quarterly amount awarded from public contracts

WallStreetBets

Number of mentions of OMER in WallStreetBets Daily Discussion

OMER News

Recent insights relating to OMER

CNBC Recommendations

Recent picks made for OMER stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in OMER

OMER Top Shareholders

Shareholder	Shares Held

OMER Options Owners

Shareholder	Security	Underlying Shares

* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.

OMER Stock Smart Score

The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.

The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.

Score Breakdown

Bull Case vs Bear Case

See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.

Example:

Bulls Say:

The Bulls Say summary highlights positive aspects of the stock.

Bears Say:

The Bears Say summary points out potential risks and negative aspects of the stock.